Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation.

Claire Pearson | Emily E Thornton | Brent McKenzie | Anna-Lena Schaupp | Nicky Huskens | Thibault Griseri | Nathaniel West | Sim Tung | Benedict P Seddon | Holm H Uhlig | Fiona Powrie
eLife | 2016

Innate lymphoid cells (ILCs) contribute to host defence and tissue repair but can induce immunopathology. Recent work has revealed tissue-specific roles for ILCs; however, the question of how a small population has large effects on immune homeostasis remains unclear. We identify two mechanisms that ILC3s utilise to exert their effects within intestinal tissue. ILC-driven colitis depends on production of granulocyte macrophage-colony stimulating factor (GM-CSF), which recruits and maintains intestinal inflammatory monocytes. ILCs present in the intestine also enter and exit cryptopatches in a highly dynamic process. During colitis, ILC3s mobilize from cryptopatches, a process that can be inhibited by blocking GM-CSF, and mobilization precedes inflammatory foci elsewhere in the tissue. Together these data identify the IL-23R/GM-CSF axis within ILC3 as a key control point in the accumulation of innate effector cells in the intestine and in the spatio-temporal dynamics of ILCs in the intestinal inflammatory response.

Pubmed ID: 26780670

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: Medical Research Council, United Kingdom
    Id: MC_PC_13055
  • Agency: Arthritis Research UK, United Kingdom
    Id: 20834
  • Agency: Wellcome Trust, United Kingdom
    Id: 095688
  • Agency: Versus Arthritis, United Kingdom
    Id: 20834
  • Agency: Medical Research Council, United Kingdom
    Id: MR/L022699/1

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Bio X Cell (tool)

RRID:SCR_004997

Commercial supplier and developer of in vivo antibodies. Provides antibodies and antibody production services.

View all literature mentions

Imaris (tool)

RRID:SCR_007370

Imaris provides range of capabilities for working with three dimensional images. Uses flexible editing and processing functions, such as interactive surface rendering and object slicing capabilities. And output to standard TIFF, Quicktime and AVI formats. Imaris accepts virtually all image formats that are used in confocal microscopy and many of those used in wide-field image acquisition.

View all literature mentions

Genentech (tool)

RRID:SCR_003997

A biotechnology corporation that uses human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions.

View all literature mentions